Cancer Chemotherapy and Pharmacology

, Volume 30, Issue 3, pp 219–220 | Cite as

Phase II study of high-dose aclarubicin in previously treated patients with small-cell lung cancer

  • Peter Buhl Jensen
  • Susanne Kornum Larsen
  • Irene Stilbo
Short Communication Aclarubicin, Phase Il, Small-Cell Lung Cancer

Keywords

Lung Cancer Cancer Research Aclarubicin 

References

  1. 1.
    Aabo K, Mortensen SÅ, Skovsgaard T, Gymoese E (1983) Intermittent high-dose aclarubicin in patients with advanced cancer: a phase I study with special reference to cardiac toxicity. Cancer Treat Rep 67: 281–282Google Scholar
  2. 2.
    Abeloff MD, Finkelstein DM, Chang AYC, Camacho FJ, Creech H, Ettinger DS (1985) Phase II study of aclarubicin and diaziquone in the treatment of advanced small cell bronchogenic carcinoma (EST 4581): an Eastern Cooperative Oncology Group study. Cancer Treat Rep 69: 451–452Google Scholar
  3. 3.
    Hansen OP, Pedersen-Bjergaard J, Ellegaard J, Brincker H, Boesen AM, Christensen BE, Drivsholm A, Hippe E, Jans H, Jensen KB, Killmann S-A, Jensen MK, Karle H, Laursen B, Nielsen JB, Nissen NI, Thorling K (1991) Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. Leukemia 5: 510–516Google Scholar
  4. 4.
    Jensen PB, Vindeløv L, Roed H, Demant EJF, Sehested M, Skovsgaard T, Hansen HH (1989) In vitro evaluation of the potential of aclarubicin in the treatment of small cell carcinoma of the lung (SCCL). Br J Cancer 60: 838–844Google Scholar
  5. 5.
    Jensen PB, Jensen PS, Sehested M, Demant EJF, Sørensen BS, Vindeløv L, Hansen HH (1991) Lack of cross-resistance to aclarubicin in an altered topoisomerase II multidrug resistant (at-MDR) small cell lung cancer (SCLC) cell line. Proc Am Assoc Cancer Res 32:350Google Scholar
  6. 6.
    Jensen PB, Jensen PS, Demant EJF, Friche E, Sørensen BS, Sehested M, Wassermann K, Vindeløv L, Westergaard O, Hansen HH (1991) Antagonistic effect of aclarubicin on daunorubicin induced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase II. Cancer Res 51: 5093–5099Google Scholar
  7. 7.
    Kramer BS, Birch R, Gockerman JP, Greco A, Prestridge K (1986) Phase II evaluation of aclarubicin in lung cancer: a Southeastern Cancer Study Group trial. Cancer Treat Rep 70: 803–804Google Scholar
  8. 8.
    Machover D, Gastiaburu J, Delgado M, Goldschmidt E, Hulhoven R, Misset JL, Vassal F de, Tapiero H, Ribaud P, Schwarzenberg L, Mathé G (1984) Phase I-II study of aclarubicin for treatment of acute myeloid leukemia. Cancer Treat Rep 68: 881–886Google Scholar
  9. 9.
    Oki T, Takeuchi T, Oka S, Umezawa H (1981) New anthracycline antibiotic aclacinomycin A: experimental studies and correlations with clinical trials. Recent Results Cancer Res 76: 21–40Google Scholar
  10. 10.
    Pedersen-Bjergaard J, Brincker H, Ellegaard J, Drivsholm A, Freund L, Jensen KB, Jensen MK, Nissen NI (1984) Aclarubicin in the treatment of acute nonlymphocytic leukemia refractory to treatment with daunomycin and cytarabine: a phase II trial. Cancer Treat Rep 68: 1233–1238Google Scholar
  11. 11.
    Skovsgaard T (1987) Pharmacodynamic aspects of aclarubicin with special reference to daunorubicin and doxorubicin. Eur J Haematol 38: 7–20Google Scholar
  12. 12.
    Warrell RP, Arlin ZA, Kempin SJ, Young CW (1982) Phase I–II evaluation of a new anthracycline antibiotic, aclacinomycin A, in adults with refractory leukemia. Cancer Treat Rep 66: 1619–1623Google Scholar
  13. 13.
    WHO (1979) Handbook for reporting results of cancer treatment. World Health Organization, GenevaGoogle Scholar

Copyright information

© Springer-Verlag 1992

Authors and Affiliations

  • Peter Buhl Jensen
    • 2
  • Susanne Kornum Larsen
    • 1
  • Irene Stilbo
    • 2
  1. 1.Department of OncologyUniversity Hospital HerlevHerlevDenmark
  2. 2.Department of Oncology 5074University Hospital RigshospitaletCopenhagenDenmark

Personalised recommendations